Celltrion’s Herzuma (trastuzumab, biosimilar) Receives ANVISA’s Approval for Breast and Gastric Cancer in Brazil

Celltrion’s Herzuma (trastuzumab, biosimilar) Receives ANVISA’s Approval for Breast and Gastric Cancer in Brazil

Shots:

  • The Brazilian Health Regulatory Agency, ANVISA (Agencia Nacional de Vigilancia Sanitaria) has approved Herzuma (trastuzumab) in 150mg & 440mg for early-stage breast cancer, metastatic breast cancer and metastatic gastric cancer on May 20, 2019
  • Celltrion is also expecting ANVISA’s approval for Truxima, a biosimilar of Rituximab which helps in securing a leading market position in the Central-South American biosimilar market
  • Herzuma (trastuzumab-pkrb) is a biosimilar of Herceptin and has received FDA’s approval in Dec’18, also approved in EU (marketed by Mundipharma), in Japan (marketed by Daiichi Sankyo) and in Australia

Click here to read full press release/ article | Ref: Celltrion | Image: The Investor